Gensight BiologicsGSGTF 3-Year ROIIC % is 1,161.55 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 1,320 Biotechnology companies, Gensight Biologics ranks better than 94.55% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Gensight Biologics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,161.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Gensight Biologics's 3-Year ROIIC % or its related term are showing as below:
GSGTF's 3-Year ROIIC % is ranked better than 94.55% of 1320
companies
in the Biotechnology industry
Industry Median: -4.63
vs GSGTF: 1161.55
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Gensight Biologics 3-Year ROIIC % Related Terms
Gensight Biologics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSGTF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Gensight Biologics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's 3-Year ROIIC % falls into.
Gensight Biologics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -12.939822 (Dec. 2025) - -29.486 (Dec. 2022) )
/
( 8.936 (Dec. 2025) - 6.555 (Dec. 2022) )
=
16.546178
/
2.381
=
694.93%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Gensight Biologics (GSGTF) has a 3-Year ROIIC % of 1,161.55 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #72 out of 1320 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Gensight Biologics' 3-Year ROIIC % too high?
Gensight Biologics' current 3-Year ROIIC % is 1,161.55. Based on the distribution chart, Gensight Biologics ranks #72 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Gensight Biologics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #72 out of 1320 companies for 3-Year ROIIC %. This places Gensight Biologics in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current 3-Year ROIIC % is 1,161.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current 3-Year ROIIC % is 1,161.55. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current 3-Year ROIIC % is 1,161.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 